Slide 1: Carl Icahn Has No Actionable Plan for GRAIL and His Nominees Would Put Shareholder Value at Risk
© 2023 Illumina, Inc. All rights reserved. April 2023 Carl Icahn Has No Actionable Plan for GRAIL and His Nominees Would Put Shareholder Value at Risk
Slide 2: Forward Looking Statements
Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding mandates, the future, business plans and other statements that are not historical in nature. These statements
Slide 3: Icahn Has No Actionable Plan for GRAIL
Icahn Has No Actionable Plan for GRAIL There is nothing Carl or “his guys” can do to accelerate the divesture of GRAIL Abandoning Illumina’s legal challenge in the EU would not necessarily speed up divestiture either and certainly not optimize shareholder value Illumina is moving as quickly as possi
Slide 4: Replacing Even One of Illumina's Highly Qualified Nominees with Icahn's Would Put Shareholder Value at Risk
Replacing Even One of Illumina’s Highly Qualified Nominees with Icahn’s Would Put Shareholder Value at Risk Risk Management Public Company Executive Life Sciences Technology & Innovation Regulatory Experience Financial Expertise International Experience MD / PhD John Thompson Francis deSouza Robert
Slide 5: Board Reflects Purpose-Built Mix of Skills and Diversity
Illumina’s Board Reflects Purpose-Built Mix of Skills and Diversity Director Skillsets 56% Gender / Racial Diversity 89% Board Independence Risk Oversight / Management Skill critical for understanding Illumina’s risks and opportunities 7 directors Life Sciences Skill critical for understanding Illum
Slide 6: Board Has Been Deliberate in its Director Refreshment
Illumina’s Board Has Been Deliberate in its Director Refreshment Icahn is deluded about Francis deSouza’s role in Illumina’s nomination process Francis has not nominated a single director to the board The facts about Illumina’s director nomination process: Illumina’s Nominating/Corporate Governance
Slide 7: Innovation Engine Continues to Generate Breakthrough Products
Illumina’s Innovation Engine Continues to Generate Breakthrough Products First FDA-registered and CE-marked IVD high- throughput sequencer NovaSeq 6000 Dx 2020 2022 2023 NovaSeq X & NovaSeq X Plus Breakthrough high throughput sequencer with 2x speed and 2.5x throughput improvement 75 breakthrough in